ICU Medical Completes the Acquisition of Hospira Infusion Systems from Pfizer

 

The addition of Hospira’s I.V. pumps, solutions, and devices business to ICU Medical’s existing portfolio creates a leading pure-play infusion therapy company with focus and global scale

SAN CLEMENTE, CA February 6, 2017 ICU Medical Inc. (NASDAQ: ICUI) today announced that it has completed its acquisition of the Hospira Infusion Systems (HIS) business from Pfizer Inc. (NYSE: PFE). The Hospira Infusion Systems business includes I.V. pumps, solutions, and devices that, when combined with the company’s existing businesses, makes ICU Medical one of the world’s leading pure-play infusion therapy companies.

“We are pleased that Hospira Infusion Systems is now part of ICU Medical and welcome our new Hospira colleagues to the ICU team. We look forward to working together to continue providing quality, innovation and value to our clinical customers worldwide,” said Vivek Jain, chairman and chief executive officer at ICU Medical.

The Hospira Infusion Systems acquisition complements ICU Medical’s existing business to create a company with a complete I.V. therapy product portfolio from solutions to pumps to non-dedicated infusion sets. In addition, the acquisition gives ICU Medical a significantly enhanced global footprint and platform for continued competitiveness and long-term growth. With an integrated product offering, the company now holds industry-leading positions in key segments and has access to the full US infusion marketplace with a compelling product portfolio.

The company plans to announce full FY 2017 guidance on its Q4 Earnings call in late February.

See our complete infusion therapy portfolio